March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Evidence that Dopamine Acts Upstream of Nitric Oxide in the Signal Cascade Mediating Ocular Growth Inhibition
Author Affiliations & Notes
  • Kristen Totonelly
    Biosciences, New England College of Optometry, Boston, Massachusetts
  • Laimeng Lee
    Biosciences, New England College of Optometry, Boston, Massachusetts
  • Andy T. Cheng
    SUNY Optometry, New York, New York
  • Debora L. Nickla
    Biosciences, New England College of Optometry, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Kristen Totonelly, None; Laimeng Lee, None; Andy T. Cheng, None; Debora L. Nickla, None
  • Footnotes
    Support  NIH Grant EY013636
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4660. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kristen Totonelly, Laimeng Lee, Andy T. Cheng, Debora L. Nickla; Evidence that Dopamine Acts Upstream of Nitric Oxide in the Signal Cascade Mediating Ocular Growth Inhibition. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4660.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Evidence from animal models of myopia indicate that both dopamine and nitric oxide (NO) may play a role in ocular growth inhibition: quinpirole (D2 agonist) prevents the development of both form deprivation- and negative lens-induced myopia, and nitric oxide synthase (NOS) inhibitors prevent the growth inhibition that results from imposing myopic defocus using positive lenses (Nickla et al., 2009). We sought to determine if dopamine and NO act on the same pathway, and if so, which is upstream.

Methods: : One eye of 12 d-old chicks wore either a -10 D lens, or a translucent diffuser (FD) for 5 days. Each paradigm was divided into four groups and experimental eyes were injected daily for 4 days: (1) Quinpirole: 20 µl injections (FD: n=21; Lens: n=13); (2) Both: 10 µl quinpirole + 10 µl n-omega-propyl-L-arginine (n-PLA; nNOS inhibitor) (n=17; n=23); (3) N-PLA: 20 µl (n=4; n=10); (4) Saline: 20 µl (n=20; n=35). Ocular dimensions were measured using high frequency A-scan ultrasonography before, and on the last day immediately prior to and 3 hours after injections. Refractions were measured on the last day. In one lens experiment, NO was measured in eyecups using the in-NO amperometric system after the final measures.

Results: : As expected, quinpirole alone largely prevented the development of myopia in both paradigms (exp vs saline: FD: -3.4 D vs -6.2 D; Lens: -0.4 D vs -4.7 D; p<0.01 for both) due to the inhibition of the growth of the vitreous chamber (FD: 290 vs 364 µm; p=0.08: Lens: 277 vs 353 µm; p<0.05). By contrast, co-injecting quinpirole with n-PLA inhibited the effect of quinpirole: eyes became more myopic than with quinpirole alone (FD: -5.9 D vs -3.4 D; Lens: -3.5 D vs -0.4 D; p<0.05 for both) as a result of faster growth (FD: 401 vs 290 µm; Lens: 407 vs 277 µm; p<0.05). In the lens group, co-injections also prevented the quinpirole-induced transient choroidal thickening (0 µm vs 31 µm/3 hrs; p<0.05). In vitro, eyecups from quinpirole-injected eyes produced more NO over 24 hrs than those of their fellow controls (paired t-test; p<0.005).

Conclusions: : The finding that the nNOS inhibitor blocks the inhibitory action of quinpirole on eye growth suggests that dopamine acts upstream of NO in the same pathway of the signal cascade mediating ocular growth inhibition.

Keywords: dopamine • emmetropization • nitric oxide 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.